10X Genomics Inc TXG

$69.89 +0.03 (0.04%)

Valuation

Market cap
9,102,129,000
Revenue TTM
$642,820,000
Net income TTM
$-43,540,000
PE ratio
0.00
Forward PE
—
Profit margin
-6.77%
Debt to equity
0.00

Trading

Volume
2,527,000
Avg volume
3,471,586
Day's range
$68.50 – $72.48
Shares out
130,291,000
Stochastic %K
13%
Beta
1.99
Analysts
Sell
Price target
$77.82

Price

Company profile

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromiu...

Show more

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Industry
Medical Devices
Sector
Healthcare
Phone
925 401 7300
Website
https://www.10xgenomics.com
Address
6230 Stoneridge Mall Road, Pleasanton, United States

Latest news

Stocktwits

Dr_Stoxx Oct 19, 2:14 PM
$TXG on the short list. Medtech play, ARK fave. Indicators lined up nicely for a bounce off the pullback. Just a bit too much downside momo however...will take a strong move to overcome.
0 replies
Tangidong Oct 17, 8:49 AM
$TXG when Atera is coming?
1 replies
Tangidong Oct 16, 3:15 PM
$TXG new entry price? $65?
0 replies
strassburg Oct 14, 8:46 AM
$TXG Bought at $32. I should of sold in the $90S obviously. I got a little greedy. It just kept going up and up. I sold mid 70s. Still a profitable trade and I think this is a really cool company. I plan on re-entering when the dust settles. GLTA
0 replies
bert007123 Oct 13, 8:11 PM
$TXG Dead
0 replies
SuperGreenToday Oct 13, 5:24 AM
$TXG Share Price: $75.24 Contract Selected: May 21, 2027 $75 Calls Buy Zone: $21.97 – $27.14 Target Zone: $41.58 – $50.82 Potential Upside: 79% ROI Time to Expiration: 220 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
bidenomics_man Oct 13, 4:06 AM
$TXG bulls never listen, they always get fucked time and time again, it's just nature, there has to be losers for there to be winners, simply natural selection, the high iq bear wins and rapes the low iq bull to assert dominance
0 replies
bidenomics_man Oct 13, 4:03 AM
$TXG going back to $50 , you bulltards are delusional if you think all the buyers from the last 3 months are long-term, this is going to get violent for these low iq baggies, you all disgust me, I would spit on you if I saw you
0 replies